FDA Grants Meeting to Petros Pharmaceuticals to Discuss Label Expansion of Erectile Dysfunction Drug STENDRA® - PRNewswire
NEW YORK , July 27, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI) ("Petros," or "the Company"), a leading provider of therapeutics for men's health, today announces it has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss expansions and modifications to the labeling of its erectile dysfunction (ED) medication, STENDRA ® (avanafil). The meeting is currently scheduled for September, 2021. Stendra (avanafil), is an FDA-approved, prescription oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of ED. "We are grateful for the opportunity to review our label with the United States Food and Drug Administration and to propose some potential changes that we believe the breadth and depth of clinical experience with STENDRA may warrant. The granting of this meeting with the agency follows closely our initiation of activities that we hope will result in a separate request to consider bringing ST